@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix chebi: . @prefix sfam: . @prefix proteinModification: . @prefix psimod: . @prefix species: . @prefix occursIn: . @prefix obo: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 belv:variantOf sfam:RAS%20Family; a proteinModification:, psimod:00437 . sub:_2 occursIn: obo:CL_0000182, species:10116; rdf:object sub:_1; rdf:predicate belv:decreases; rdf:subject chebi:6544; a rdf:Statement . sub:assertion rdfs:label "a(CHEBI:lovastatin) -| p(SFAM:\"RAS Family\",pmod(F,L))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_4; pav:version "20131211" . sub:_3 prov:value "Wortmannin and LY294002, PI3-kinase inhibitors, as well as lovastatin and PD152440, Ras farnesylation inhibitors, and MEK inhibitor PD98059 abolished the insulin repression of ALAS transcription."; prov:wasQuotedFrom pubmed:11716532 . sub:_4 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:11716532; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:31:44.842+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }